BusinessHorizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis CommunityBy Nasdaq OMXJan 30, 2018, 1:30 PM UTC
BusinessHorizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic CystinosisBy Nasdaq OMXDec 27, 2017, 1:00 PM UTC
BusinessHorizon Pharma plc Announces Availability of PROCYSBI™ (cysteamine bitartrate) in CanadaBy Nasdaq OMXOct 26, 2017, 12:01 PM UTC
BusinessHorizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules at Cystinosis Research Network 2017 Family ConferenceBy Nasdaq OMXJul 14, 2017, 12:00 PM UTC
BusinessHorizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic CystinosisBy Nasdaq OMXJun 19, 2017, 12:00 PM UTC
BusinessRaptor Pharmaceutical to Participate in the Leerink Partners 5th Global Healthcare ConferenceBy Nasdaq OMXFeb 8, 2016, 12:30 PM UTC
